Welcome to our dedicated page for Akebia Therapeut SEC filings (Ticker: AKBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Akebia Therapeutics, Inc. (Nasdaq: AKBA) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering investors structured access to its official communications. As a biopharmaceutical company focused on kidney disease, Akebia uses filings such as Forms 8-K, 10-K, and 10-Q to report material agreements, financial performance, and key clinical and regulatory developments related to products like Vafseo (vadadustat) and Auryxia (ferric citrate), as well as its rare kidney disease pipeline.
Recent 8-K filings illustrate the type of information investors can expect. One filing describes an amendment to Akebia’s License Agreement with MEDICE Arzneimittel Putter GmbH & Co. KG, under which Akebia supplies vadadustat drug substance and Medice has rights to manufacture Vafseo tablets for Europe and certain other countries, with resulting know-how and patent rights owned by Akebia. Other 8-Ks furnish quarterly financial results, highlight business updates such as Vafseo commercialization metrics, and disclose regulatory decisions, including Akebia’s announcement that it does not plan to initiate the VALOR trial and does not expect to pursue a broad label for Vafseo in CKD patients not on dialysis.
Through this page, users can review annual reports on Form 10-K for comprehensive discussions of risk factors, product portfolios, and strategy; quarterly reports on Form 10-Q for interim financial and operational updates; and current reports on Form 8-K for material events. Insider transaction reports on Form 4, when available, provide visibility into equity transactions by directors and officers. Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight material changes, and help readers quickly understand how new disclosures may relate to Akebia’s kidney disease programs and overall business.
State Street Corporation has disclosed a passive ownership stake in Akebia Therapeutics Inc. common stock on a Schedule 13G. As of 12/31/2025, State Street reported beneficial ownership of 13,687,561 shares, representing 5.2% of Akebia’s outstanding common stock.
State Street reported no sole voting or dispositive power over these shares, but shared voting power over 13,169,907 shares and shared dispositive power over 13,687,561 shares. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of Akebia.
Akebia Therapeutics SVP and Chief Accounting Officer Richard C. Malabre reported two stock sales of Akebia Therapeutics, Inc. common shares. On February 2, 2026, he sold 36,142 shares at $1.39 per share and 13,382 shares at $1.39 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025, and were made automatically by the company to cover tax withholding obligations related to vesting of restricted stock units granted on January 31, 2024 and January 31, 2025. After these transactions, Malabre directly owned 299,390 common shares of Akebia.
Akebia Therapeutics chief commercial officer Nicholas Grund reported sales of company stock. On February 2, 2026, he sold 53,585 shares of Akebia common stock at $1.39 per share, followed by an additional sale of 31,244 shares at the same price.
According to the footnotes, one sale was made under a pre-arranged Rule 10b5-1 trading plan, and other sales were made automatically by Akebia to cover tax withholding tied to the vesting and settlement of restricted stock units granted in January 2024 and January 2025. After these transactions, Grund directly owned 561,750 shares of Akebia common stock.
Akebia Therapeutics SVP and Chief Medical Officer Steven K. Burke reported routine share sales tied to equity compensation and a pre-set plan. On February 2, 2026, he sold 21,582, 25,375, and 20,701 shares of common stock, each at $1.39 per share.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on November 17, 2023, and the other two were automatic sales by Akebia to cover tax withholding obligations upon vesting of restricted stock units granted in 2023, 2024, and 2025. After these transactions, Burke directly beneficially owned 948,432 shares of Akebia common stock.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported multiple automatic stock sales tied to equity compensation. On February 2, 2026, she sold 16,846, 25,382, and 27,544 shares of Akebia common stock at $1.39 per share in separate transactions.
The filing states one sale was made under a Rule 10b5-1 trading plan adopted on September 8, 2025. The other sales were made automatically by Akebia to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on January 31, 2023, January 31, 2024, and January 31, 2025. After these transactions, Rucci directly beneficially owned 588,378 shares of common stock.
Akebia Therapeutics, Inc. executive Erik Ostrowski, who serves as SVP, CFO, CBO and Treasurer, reported a sale of common stock. On February 2, 2026, he sold 34,951 shares at $1.39 per share.
According to the filing, the sale was made automatically by Akebia to cover tax withholding obligations tied to the vesting and settlement of one-third of his restricted stock units granted on January 31, 2025. The transaction was carried out under a Rule 10b5-1 trading plan adopted on September 8, 2025. After this transaction, he beneficially owns 672,635 shares of Akebia common stock directly.
Akebia Therapeutics CEO and President John P. Butler, who is also a director, reported several transactions in Akebia common stock on February 2, 2026. He sold 46,660, 96,065, 114,891, and 83,689 shares at $1.39 per share. According to the footnotes, most of these sales were made automatically by the company to cover tax withholding when restricted stock units and performance stock units vested, and were executed under a Rule 10b5-1 trading plan adopted on September 8, 2025. Butler also acquired 175,250 shares at $1.41 per share upon vesting of performance-based restricted stock units after a stock price performance condition was certified and met. Following these transactions, he directly held 3,297,794 shares and indirectly held 159,928 shares through the Dorothy Butler Revocable Trust dated November 20, 2007.
Akebia Therapeutics’ Chief Commercial Officer Nicholas Grund received new equity awards, aligning his compensation with company performance. On January 30, 2026, he was granted 204,000 shares of common stock as restricted stock units at $0.00 per share, bringing his directly owned common stock to 646,579 shares.
He was also granted a stock option for 320,000 shares of common stock at an exercise price of $1.41 per share, expiring on January 30, 2036. The RSUs vest in three equal annual installments, while the options vest over four years, both subject to his continued service.
Akebia Therapeutics disclosed that SVP and Chief Medical Officer Steven K. Burke received new equity awards on January 30, 2026. He was granted 204,000 restricted stock units of common stock at no cost and 320,000 stock options with a $1.41 exercise price.
The 204,000 restricted stock units vest in three equal installments on the first, second, and third anniversaries of the grant date, conditioned on continued service. The 320,000 options vest over four years, with 25% after one year and the remaining 75% in equal quarterly installments. Following the grant, Burke directly beneficially owns 1,016,090 shares of common stock, including 3,000 shares acquired through the company’s employee stock purchase plan.
Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported new equity awards. On January 30, 2026, she received 190,000 shares of common stock in the form of restricted stock units at $0.00 per share, bringing her directly held common stock to 658,150 shares.
She was also granted a stock option for 270,000 shares of common stock with a $1.41 exercise price, all held directly. The restricted stock units vest in three equal annual installments, while the options vest over four years, both subject to continued service with the company.